Profile data is unavailable for this security.
About the company
Neuland Laboratories Limited is an India-based company. The Company is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The Company is an active pharmaceutical ingredient (API) manufacturing and development organization that caters to the pharmaceutical and biotech industry’s chemistry needs. It provides solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying New Chemical Entities (NCEs) and advanced intermediates at various stages in the clinical life cycle, as well as commercial launch. The Company has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its key molecules include Mirtazapine, an anti-depressant and Levetiracetam, an anti-epileptic agent. The Company’s product portfolio includes over 100 APIs across 10 diverse therapeutic areas.
- Revenue in INR (TTM)16.35bn
- Net income in INR3.36bn
- Incorporated1984
- Employees1.65k
- LocationNeuland Laboratories Ltd'A' Block, Ground Floor, 8-2-120/113Rd No 2, Banjara Hills, Sanali Info ParkHYDERABAD 500033IndiaIND
- Phone+91 4 067611600
- Fax+91 4 067611600
- Websitehttps://www.neulandlabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Life Sciences Ltd | 22.05bn | 4.24bn | 129.54bn | 2.01k | 30.67 | 5.10 | 26.95 | 5.88 | 34.47 | 34.47 | 179.44 | 207.17 | 0.7304 | 1.46 | 2.79 | 10,947,850.00 | 14.03 | 18.28 | 16.69 | 29.99 | 54.92 | 53.40 | 19.21 | 20.23 | 3.03 | 380.55 | 0.0063 | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Marksans Pharma Ltd | 22.68bn | 3.34bn | 131.26bn | 2.00k | 39.29 | -- | 31.66 | 5.79 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 132.51bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Granules India Ltd | 47.01bn | 4.92bn | 138.05bn | 4.12k | 28.07 | -- | 19.64 | 2.94 | 20.29 | 20.29 | 193.87 | -- | -- | -- | -- | 11,403,970.00 | -- | 10.68 | -- | 16.18 | 56.89 | 48.83 | 10.47 | 11.82 | -- | 6.95 | -- | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Strides Pharma Science Ltd | 44.10bn | 1.77bn | 143.04bn | 3.07k | 80.93 | 6.29 | 38.48 | 3.24 | 19.22 | 25.15 | 479.84 | 247.16 | 0.7155 | 1.50 | 3.57 | 14,389,290.00 | 2.79 | -1.68 | 5.43 | -2.97 | 60.19 | 51.39 | 3.91 | -3.36 | 0.6355 | 1.52 | 0.5103 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Caplin Point Laboratories Ltd | 17.58bn | 4.78bn | 154.71bn | 859.00 | 32.48 | -- | 28.64 | 8.80 | 62.67 | 62.67 | 230.62 | -- | -- | -- | -- | 20,462,630.00 | -- | 19.83 | -- | 22.82 | 58.41 | 53.38 | 27.43 | 25.39 | -- | 1,525.59 | -- | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Sanofi India Ltd | 23.83bn | 4.30bn | 156.48bn | 2.17k | 36.41 | 22.86 | 33.44 | 6.57 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Eris Lifesciences Ltd | 24.98bn | 3.48bn | 180.09bn | 3.08k | 51.74 | 6.49 | 28.91 | 7.21 | 25.57 | 25.57 | 183.35 | 203.74 | 0.4585 | 2.90 | 5.96 | 8,110,753.00 | 6.73 | 13.42 | 8.39 | 16.80 | 77.03 | 79.98 | 14.69 | 24.96 | 0.8599 | 3.41 | 0.4626 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Wockhardt Ltd | 28.93bn | -3.43bn | 185.39bn | 2.39k | -- | -- | -- | 6.41 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 187.40bn | 1.65k | 55.76 | -- | 47.03 | 11.46 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 190.62bn | 940.00 | 198.86 | -- | 171.87 | 13.74 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Concord Biotech Ltd | 10.38bn | 3.13bn | 191.48bn | 1.38k | 61.15 | -- | 52.18 | 18.45 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Jubilant Pharmova Ltd | 69.20bn | 5.93bn | 191.94bn | 995.00 | 32.41 | 3.23 | 19.86 | 2.77 | 37.38 | 37.38 | 436.41 | 375.04 | 0.5934 | 1.75 | 8.15 | 69,544,720.00 | 5.05 | 2.96 | 6.01 | 3.55 | 68.50 | 68.47 | 8.51 | 5.13 | 1.20 | 2.51 | 0.342 | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 221.89bn | 14.86k | 35.23 | -- | 24.51 | 3.52 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Pfizer Ltd | 22.38bn | 6.18bn | 233.22bn | 1.72k | 37.75 | 6.22 | 34.36 | 10.42 | 135.06 | 135.06 | 489.19 | 819.90 | 0.5288 | 1.83 | 11.16 | 13,004,360.00 | 14.60 | 14.22 | 17.05 | 17.71 | 65.00 | 61.37 | 27.61 | 24.05 | 4.30 | 46.21 | 0.0267 | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Natco Pharma Ltd. | 42.21bn | 16.37bn | 251.28bn | 4.02k | 15.35 | -- | 13.78 | 5.95 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
Data as of Nov 01 2024. Currency figures normalised to Neuland Laboratories Ltd's reporting currency: Indian Rupee INR
19.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Matthews International Capital Management LLCas of 30 Sep 2023 | 522.35k | 4.07% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 483.09k | 3.77% |
| HSBC Asset Management (India) Pvt Ltd.as of 30 Sep 2024 | 328.32k | 2.56% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 311.06k | 2.42% |
| Jupiter Asset Management Ltd.as of 30 Jun 2024 | 192.56k | 1.50% |
| quant Money Managers Ltd.as of 30 Sep 2023 | 192.07k | 1.50% |
| Ocean Dial Asset Management Ltd.as of 30 Sep 2023 | 170.89k | 1.33% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 111.28k | 0.87% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 91.87k | 0.72% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 85.72k | 0.67% |
More ▼
Data from 30 Jun 2024 - 15 Oct 2024Source: FactSet Research Systems Inc.
